Skip to main content
Premium Trial:

Request an Annual Quote

Pronota Receives $2M to Further Development of Cardiovascular Biomarkers

Premium

This story originally ran on Jan. 13.

Belgian biomarker firm Pronota this week announced it has been awarded €1.4 million ($2 million) to further validate and develop novel cardiovascular protein biomarkers.

The grant comes from the Institute for the Promotion of Innovation by Science and Technology in Flanders and will be used to validate and characterize candidate biomarkers discovered using Pronota's MASStermind platform. It also will be used to develop generic immuno-based assays for lead candidates. The assays will be used for the final clinical validation in a large, multicenter, clinical trial and for regulatory submission, the company said in a statement.

Koen Kas, founder and chief scientific officer of Pronota, said in the statement that the award "provides us with the means to address a significant clinical and commercial opportunity, which should prove the era of clinical proteomics has finally arrived."

During the summer the company announced it had raised €4.9 million in a Series B financing round. Then in October, it said it raised another €1.3 million. The funds from both tranches would be used to hasten the company's diagnostics development programs, including one targeting heart failure.

Pronota CEO Nick McCooke told ProteoMonitor in July that the firm had identified 10 candidate biomarkers for heart failure. Two existing biomarkers exist for diagnostic purposes, brain natriuretic peptide, or BNP, and N-terminal fragment BNP, or NT-proBNP. Both have limitations, however, including no definitive level that delineates patients with heart failure from those without resulting in a diagnostic gray area.

The company is developing its own biomarkers to address the weaknesses of BNP and NT-proBNP, McCooke said [See PM 07/09/09].

The company is targeting early 2012 for its first commercial product launch.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.